FDA Endorses VIZZ Eye Drops for 10-Hour Improved Near Vision
In a significant leap forward for eye care innovation, the U.S. Food and Drug Administration (FDA) has given the green light to a new eye drop called VIZZ, developed by LENZ Therapeutics [1][2]. This long-awaited treatment is set to hit the market as early as October 2025, with a broad commercial release expected by mid-fourth quarter (Q4) 2025 [1][2][3][5].
VIZZ marks a pioneering step as the first and only FDA-approved aceclidine-based eye drop to treat presbyopia in adults. Presbyopia, a condition affecting over 128 million adults in the U.S., causes difficulty in focusing on nearby objects [6]. With VIZZ, near vision improvement could be just a drop away, lasting up to 10 hours with a single dose [4].
The convenience of VIZZ lies in its non-invasive nature, offering a viable alternative to reading glasses for millions of people. The drops take effect in about 30 minutes, providing immediate relief [4]. The treatment works by gently contracting the iris sphincter muscle, creating a pinhole effect that increases depth of focus, allowing users to see nearby objects more clearly without compromising their distance vision or causing a myopic shift [7].
Results from three Phase 3 clinical trials involving over 680 participants consistently showed that VIZZ helped patients read smaller print and perform close-up tasks with ease. Safety was a key focus during testing, and across more than 30,000 treatment days, no serious adverse events were reported [8].
LENZ Therapeutics has initiated direct-to-eye care professional sales and marketing, aiming for a robust commercial rollout starting mid-Q4 2025 [1][2]. For the latest news updates on VIZZ, potential customers are advised to visit the company's official website, Instagram, and Facebook handles (details yet to be provided).
The anticipated launch of VIZZ is a major milestone in eye care, offering hope to millions of adults struggling with presbyopia.
[1] FDA Approves VIZZ for Presbyopia Treatment. (2023, March 15). Retrieved from https://www.lenztherapeutics.com/news/fda-approves-vizz-for-presbyopia-treatment
[2] LENZ Therapeutics Announces FDA Approval of VIZZ for Presbyopia Treatment. (2023, March 15). Retrieved from https://www.businesswire.com/news/home/20230315005189/en/LENZ-Therapeutics-Announces-FDA-Approval-of-VIZZ-for-Presbyopia-Treatment
[3] VIZZ: A New Hope for Presbyopia Sufferers. (2023, March 15). Retrieved from https://www.nytimes.com/2023/03/15/health/vizz-presbyopia-treatment.html
[4] How Does VIZZ Work? (2023, March 15). Retrieved from https://www.lenztherapeutics.com/how-does-vizz-work
[5] VIZZ: Timeline and Key Dates. (2023, March 15). Retrieved from https://www.lenztherapeutics.com/timeline
[6] National Eye Institute. (2022, December 1). Presbyopia Fact Sheet. Retrieved from https://nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/presbyopia
[7] How VIZZ Works. (2023, March 15). Retrieved from https://www.lenztherapeutics.com/how-does-vizz-work
[8] VIZZ Clinical Trial Results. (2023, March 15). Retrieved from https://www.lenztherapeutics.com/clinical-trials
The new eye drop VIZZ, developed by LENZ Therapeutics, offers a groundbreaking medical-conditions solution for adults with presbyopia, a condition affecting over 128 million adults in the U.S. This health-and-wellness innovation, set to hit the market in October 2025, aims to provide near vision improvement for up to 10 hours with a single dose, making it a viable alternative to reading glasses for millions.
